NanoString Blog
Oncology
The IO Revolution, Part 3 of 4: The Role of the Tumor in the Cancer Immunity Cycle
Part one of this four-part series looked at how host, tumor, and environmental factors shape tumor-immune system interactions. Part two further examined the role of the host, and in this…
Oncology
The IO Revolution, Part 2 of 4: The Role of the Host in the Cancer Immunity Cycle
Part one of this four-part series looked at how host, tumor, and environmental factors shape tumor-immune system interactions. In the next few blogs, we will consider how each of these…
Miscellaneous Oncology
Presidents, Rock Stars and Companion Diagnostics: 2016 Review of Immunotherapy
President Jimmy Carter announced this spring that he no longer needed treatments for the metastatic melanoma found in his brain–after treatment with pembrolizumab (Keytruda, Merck), his physicians could no longer…
Events
ASH 2016: Subtyping in Diffuse Large B-Cell Lymphoma
NanoString at ASH 2016. We attended the annual meeting of the American Society of Hematology (ASH) in San Diego. The convention center was abuzz with scientists…
Publication Watch
The Cancer Immunogram: A Picture of Personalized Medicine
What do we already know about tumor-immune system interactions, and how can this information be used to help guide us toward the best therapeutic choice? That is exactly the question…
Events
SITC 2016 Recap
Looking beyond anti-PD1/PDL1 with combination therapy and gene signature testing
Oncology
The IO Revolution, Part 1 of 4: Opportunities and Challenges
Immuno-oncology (IO) focuses on harnessing the tremendous power of the human immune system to detect and destroy cancer cells.